Multi-omics Mendelian Randomization Results for IBS Drug Target Discovery

A 2026 analysis by Huiwen Ke integrates summary statistics from a large-scale IBS genome-wide association study (53,400 cases and 433,201 controls) with blood expression quantitative trait loci data. The dataset likely contains results from a druggable genome-wide Mendelian randomization analysis evaluating 5,642 potential druggable protein-coding genes. It identifies and prioritizes genetically validated drug targets, such as EP300 and P2RY14, for irritable bowel syndrome.

Use Cases

• Validate causal gene associations for irritable bowel syndrome based on integrated GWAS and eQTL data.
• Prioritize candidate drug targets for therapeutic development using Mendelian randomization results.
• Assess potential on-target adverse effects by referencing phenome-wide association study findings.
• Identify existing compounds for molecular docking predictions based on prioritized protein targets like EP300.

Strengths

• Integrates summary statistics from a large GWAS with 53,400 cases and 433,201 controls.
• Evaluates causal effects for 5,642 potential druggable protein-coding genes.
• Includes validation steps such as colocalization analysis and phenome-wide association study.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect methodological bias inherent to the specific Mendelian randomization and colocalization approaches used.

Provenance

Source

figshare

Collection Method

Systematic druggable genome-wide Mendelian randomization analysis integrating GWAS and eQTL summary statistics.

Freshness

Last updated 2026-05-18 22:02:54; freshness should be verified.